UB Paderborn / Katalog / Suche / in CDI

1 – 21 von 21

Sortiert nach

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

Clinical cancer research, 2017-08, Vol.23 (15), p.4251-4258

2017

Volltextzugriff (PDF)

Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease

Thorax, 1996-08, Vol.51 (8), p.819-824

1996

Volltextzugriff (PDF)

Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients

Journal of clinical oncology, 1995-10, Vol.13 (10), p.2600-2605

1995

Volltextzugriff (PDF)

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

The lancet respiratory medicine, 2021-06, Vol.9 (6), p.585-592

2021

Volltextzugriff (PDF)

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2015-11, Vol.90 (2), p.249-254

2015

Volltextzugriff (PDF)

Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls

Thorax, 1997-04, Vol.52 (4), p.338-341

1997

Volltextzugriff (PDF)

Energy balance in nonsmall cell lung carcinoma patients before and after surgical resection of their tumors

Cancer, 1997-02, Vol.79 (4), p.717-723

1997

Volltextzugriff (PDF)

Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial

JNCI : Journal of the National Cancer Institute, 2023-12, Vol.115 (12), p.1515-1525

2023

Volltextzugriff (PDF)

The enhanced inflammatory response in non-small cell lung carcinoma is not reflected in the alveolar compartment

Respiratory medicine, 1998, Vol.92 (1), p.76-83

1998

Volltextzugriff (PDF)

Analysis of the energy balance in lung cancer patients

Cancer research (Chicago, Ill.), 1994-12, Vol.54 (24), p.6430-6433

1994

Volltextzugriff (PDF)

LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

Annals of oncology, 2021-09, Vol.32, p.S1327-S1327

2021

Volltextzugriff (PDF)

Expression of E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in non-small-cell lung carcinoma

Virchows Archiv : an international journal of pathology, 1996-04, Vol.428 (1), p.21-27

1996

Volltextzugriff (PDF)

The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma

British journal of cancer, 1997, Vol.76 (12), p.1630-1635

1997

Volltextzugriff (PDF)

LBA92Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): a statistical analysis plan

Trials, 2021-02, Vol.22 (1), p.168-13, Article 168

2021

Volltextzugriff (PDF)

Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial

Journal of clinical oncology, 2023-08, Vol.41 (22), p.3805-3815

2023

Volltextzugriff (PDF)

Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study

Annals of oncology, 2017-09, Vol.28, p.v494

2017

Volltextzugriff (PDF)

Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)

Annals of oncology, 2019-10, Vol.30, p.v931-v932

2019

Volltextzugriff (PDF)

LBA92 - Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)

Annals of oncology, 2019-10, Vol.30, p.v931-v932

2019

Volltextzugriff (PDF)

A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)

Annals of oncology, 2017-04, Vol.28, p.ii49

2017

Volltextzugriff (PDF)

1 – 21 von 21

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(21)

Sprache

Englisch
(21)
Japanisch
(2)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer

Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease

Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients

Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial

Comparison of clinical outcome after first-line platinum-based chemotherapy in different types of KRAS mutated advanced non-small-cell lung cancer

Metabolism in patients with small cell lung carcinoma compared with patients with non-small cell lung carcinoma and healthy controls

Energy balance in nonsmall cell lung carcinoma patients before and after surgical resection of their tumors

Quality of life after patient-initiated vs physician-initiated response to symptom monitoring: the SYMPRO-Lung trial

The enhanced inflammatory response in non-small cell lung carcinoma is not reflected in the alveolar compartment

Analysis of the energy balance in lung cancer patients

LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22

Expression of E-selectin, intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1 in non-small-cell lung carcinoma

The effects of treatment with chemotherapy on energy metabolism and inflammatory mediators in small-cell lung carcinoma

LBA92Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR -mutated nonsmall cell lung cancer

MEDIASTinal staging of non-small cell lung cancer by endobronchial and endoscopic ultrasonography with or without additional surgical mediastinoscopy (MEDIASTrial): a statistical analysis plan

Endosonography With or Without Confirmatory Mediastinoscopy for Resectable Lung Cancer: A Randomized Clinical Trial

Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: Non-interventional LUME-BioNIS study

Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)

LBA92 - Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)

A non-interventional biomarker study in patients (pts) with non-small cell lung cancer (NSCLC) of adenocarcinoma histology who are treated with nintedanib according to the approved label (LUME-BioNIS)

Suchergebnisse filtern